Browse Glazer, William M.

1-20 out of 20 article(s)

Title	Type	Date	Words
Rebuttal: questioning the validity of 'anatomy of an epidemic (part II); do Whitaker's allegations endanger the trust that doctors develop with their patients?		Nov 1, 2011	2748
Rebuttal: questioning the validity of 'anatomy of an Epidemic' (Part 1): Whitaker's claims are "sensational" but scientifically unsound.		Oct 1, 2011	1575
A new antidepressant: Vilasodone (Viibryd) introduces a new and unique mechanism of action.	Drug overview	Sep 1, 2011	1239
The new wave of SGAs: will high hopes for three new antipsychotics translate into better outcomes?		Jul 1, 2011	1467
Can medications prevent PTSD after trauma? Research provides hope for understanding the underlying mechanisms and reducing occurrence.		May 1, 2011	1663
Mitigating risks in antipsychotic prescribing: as tardive dyskinesia research continues, wise presenters are taking careful progress notes.		Apr 1, 2011	1371
Current trends in psychopharmacologic management of alcoholism.		Jan 1, 2011	1537
Ketamine: a fast-acting antidepressant? Researchers identify a pathway associated with a faster onset of antidepressant effects.	Report	Oct 1, 2010	1303
The quest for the correct dose: recent efforts shed light on antipsychotic dosing, but find much work is left to be done.		Sep 1, 2010	1279
Tools help family doctors treat anxiety: behavioral health experts validate screening tool and treatment model for anxiety disorders.	Report	Jul 1, 2010	1444
Anticonvulsants can help, but how? Anticonvulsant medications appear to help in maintenance-phase SUD treatment, but no one knows exactly why.		Jun 1, 2010	1119
U.S. "way behind" on clozapine's benefits: Knowledge Network says more clozapine use will reduce schizophrenia-related suicidality.	Clinical report	May 1, 2010	1351
New tools for managing non-adherence: providers recognize the value of compliance, but what can they feasibly do about it?	Clinical report	Apr 1, 2010	1392
Tackling adherence in the real world: two clinics implement client-engagement strategies to remedy no-show issues.		Mar 1, 2010	1457
Alternatives for "difficult to treat" MDD: just 35 percent of MDD patients achieve remission with initial antidepressant monotherapy.		Feb 1, 2010	1840
In the pipeline: non-stimulant ADHD MEDS: stimulant side effects drive development of alternative medications.	Report	Jan 1, 2010	1170
More treatment options emerge: iloperidone received FDA approval last month.		Jun 1, 2009	1310
What's in the pipeline: a look at antipsychotic agents in development.		Dec 1, 2007	1224
The depot paradox: long-acting formulations of antipsychotics can boost treatment adherence rates, but clinicians have been hesitant to use them.		May 1, 2007	2199
Point-of-care tests in behavioral health: glucose monitoring and a new lithium test can provide instant results to patients and clinicians.		Apr 1, 2006	2161